A team of researchers from Department of Physics of Complex Systems at Eötvös Loránd University, Harvard Medical School, the Danish Cancer Institute, and Semmelweis University has developed an innovative approach to predict how patients with High-Grade Serous Ovarian Cancer (HGSOC) respond to chemotherapy. Their findings, to be published in NPJ Precision Oncology, a journal of the Nature group, with Oz Kilim, an ELTE PhD student, as the lead author, demonstrate that combining two key sources of information— images of tissue samples (histopathology) and detailed protein measurements (proteomics)— leads to improved accuracy in identifying which patients are likely to benefit from platinum-based chemotherapy, a common first-line treatment for ovarian cancer.Guests:Oz Kilim, PhD studentIstván Csabai, physicist